Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
ClinicalTrials.gov record
Recruiting Phase 3 Interventional

Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation

ClinicalTrials.gov ID: NCT06959095

Public ClinicalTrials.gov record NCT06959095. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search
ClinicalTrials.gov public records Last synced Oct 29, 2026, 2:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo- Controlled, Parallel-Group, Multicenter Study of the Efficacy and Safety of Depemokimab In Adult Participants With COPD With Type 2 Inflammation

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation.

Study identification

NCT ID
NCT06959095
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
981 participants

Conditions and interventions

Interventions

Biological · Drug

Eligibility (public fields only)

Age range
40 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 20, 2025 (Actual)
Primary completion
Dec 13, 2028 (Estimated)
Completion
Feb 14, 2029 (Estimated)
Last update posted
Oct 5, 2026

2025 – 2029

United States locations

U.S. sites
42
U.S. states
14
U.S. cities
37
Facility City State ZIP Site status
GSK Investigational Site Bakersfield California 93301 Recruiting
GSK Investigational Site Modesto California 95355-4046 Recruiting
GSK Investigational Site Newport Beach California 92663 Recruiting
GSK Investigational Site Wilmington Delaware 19803 Recruiting
GSK Investigational Site Bradenton Florida 34209 Recruiting
GSK Investigational Site Brandon Florida 33511-5706 Recruiting
GSK Investigational Site Hialeah Florida 33012 Recruiting
GSK Investigational Site Hialeah Florida 33016 Recruiting
GSK Investigational Site Loxahatchee Groves Florida 33470 Recruiting
GSK Investigational Site Miami Florida 33126 Recruiting
GSK Investigational Site Miami Florida 33155 Recruiting
GSK Investigational Site Miami Lakes Florida 33016 Recruiting
GSK Investigational Site Orange City Florida 32763 Recruiting
GSK Investigational Site Palm Springs Florida 33406 Recruiting
GSK Investigational Site Palmetto Bay Florida 33176-7296 Recruiting
GSK Investigational Site Pensacola Florida 32503-2698 Recruiting
GSK Investigational Site Tamarac Florida 33321 Recruiting
GSK Investigational Site Tampa Florida 33614 Recruiting
GSK Investigational Site The Villages Florida 32162 Recruiting
GSK Investigational Site Riverdale Georgia 30274 Recruiting
GSK Investigational Site Stonecrest Georgia 30038 Recruiting
GSK Investigational Site Chicago Illinois 60611 Recruiting
GSK Investigational Site Baltimore Maryland 21224 Recruiting
GSK Investigational Site Clarkston Michigan 48346 Recruiting
GSK Investigational Site Flint Michigan 48504-4730 Recruiting
GSK Investigational Site St Louis Missouri 63110 Recruiting
GSK Investigational Site Henderson Nevada 89052-5015 Recruiting
GSK Investigational Site Las Vegas Nevada 89123-2874 Recruiting
GSK Investigational Site Reno Nevada 89502 Recruiting
GSK Investigational Site North Massapequa New York 11758 Recruiting
GSK Investigational Site Winston-Salem North Carolina 27103 Recruiting
GSK Investigational Site Winston-Salem North Carolina 27104 Recruiting
GSK Investigational Site Greenville South Carolina 29607 Recruiting
GSK Investigational Site Rock Hill South Carolina 29732 Recruiting
GSK Investigational Site Franklin Tennessee 37067 Recruiting
GSK Investigational Site Corsicana Texas 75110 Recruiting
GSK Investigational Site Dallas Texas 75234 Recruiting
GSK Investigational Site Houston Texas 77058-2805 Recruiting
GSK Investigational Site Houston Texas 77084 Recruiting
GSK Investigational Site Houston Texas 77089 Recruiting
GSK Investigational Site McKinney Texas 75069 Recruiting
GSK Investigational Site Pearland Texas 77584 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 236 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06959095, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 5, 2026 · Synced Oct 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT06959095 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →